Highlights
1 patent
About
Treatment for Liver and Metabolic Disorders
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
The company’s lead product candidate, pegozafermin (BIO89-100), is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company believes that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with liver and cardiometabolic diseases, such as MASH and SHTG.
Identity
| Name | 89bio |
|---|---|
| Slug | 89bio |
| Type / kind | startup |
| Crunchbase ID | 89bio |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoL3p34AJDA |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by Roche on Sep, 2025 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Oppenheimer St 4, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://89bio.com |
|---|---|
| Careers page | https://www.89bio.com/careers |
| https://www.linkedin.com/company/54350802 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biopharmaceuticaldiabetespharmaceuticalsbiotechnologylife-sciencespatientsgastroenterology
Funding
| Total raised | $1.1B |
|---|---|
| Current stage | Public |
| Market cap | $2.2B |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}